Search
Citraconic acid
go.drugbank.com/drugs/DB04734ExperimentalCitraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.
Tryptamine
go.drugbank.com/drugs/DB08653InvestigationalCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesPitofenone
go.drugbank.com/drugs/DB15947InvestigationalCategories: Drugs for Functional Gastrointestinal DisordersEpicriptine
go.drugbank.com/drugs/DB11275ApprovedEpicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. … Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]
Octacosanol
go.drugbank.com/drugs/DB11220InvestigationalNutraceuticalIt has been studied as a potential therapeutic agent for the treatment of Parkinson's disease. … 1-octacosanol is a straight-chain aliphatic 28-carbon primary fatty alcohol that is used as a nutritional supplement.
Synonyms: n-octacosanolEW-A-401
go.drugbank.com/drugs/DB05525InvestigationalEW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.
Synonyms: EW-A-401 DNA Plasmid VectorFX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. … FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalAV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF). … As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.